Alefacept: Where it stands today

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 3, 2010, Pages 355-361

  Chaarani, Jinan ^a   Lebwohl, Mark ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alefacept; Amevive; Biologics; CD45RO+; Psoriasis

Indexed keywords

ALEFACEPT; BETAMETHASONE DIPROPIONATE; CD45RO ANTIGEN; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PLACEBO;

ACCIDENTAL INJURY; ALOPECIA AREATA; ATOPIC DERMATITIS; ATYPICAL MYCOBACTERIOSIS; BRONCHITIS; BURSITIS; CELLULITIS; CHILL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHRODERMA; GRAFT VERSUS HOST REACTION; HAILEY HAILEY DISEASE; HEART INFARCTION; HEMORRHAGIC CYSTITIS; HEPATITIS C; HUMAN; INFECTION; INFLUENZA; LICHEN PLANUS; MAXIMUM PLASMA CONCENTRATION; MEMORY T LYMPHOCYTE; NEOPLASM; PERICARDITIS SQUAMOUS CELL CANCER; PHARYNGITIS; POSTMARKETING SURVEILLANCE; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULOSIS PALMOPLANTARIS; PYODERMA; QUALITY OF LIFE; REVIEW; RHINITIS; RHINOPHARYNGITIS; SARCOIDOSIS; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE ACTIVATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VITILIGO;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PSORIASIS; RECOMBINANT FUSION PROTEINS;

EID: 77249147066     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425251003641967     Document Type: Review

References (51)

1. van de Kerkhof P, Griffiths CE, Christophers E, et al. Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. Dermatology 2005;211:256-63 • A good review of alefacept.
2. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60:824-37
3. Zachariae H, Kragballe K, Hansen HE, et al. Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol 1997;136:531-5
4. Gottlieb AB. Alefacept is well tolerated in patients with chronic plaque psoriasis. J Cutan Med Surg 2004;8(Suppl 2):14-9
5. Van der Rhee HJ TJ, Herrman WA, Waterman AH, Polano MK. Combined treatment of psoriasis with a new aromatic retinoid (Tiagson) in low dosage orally and triamcinalone acetonide cream topically: a double-blind trial. Br J Dermatol 1980;102:203-12
6. Stern RS LN, Melski J, Parrish JA, et al. Cutaneous squamus-cell carcinoma in patients treated with PUVA. N Engl J Med 1984;310:1156-61
7. Horn EJ, Fox KM, Patel V, et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 2007;57:957-62
8. Alefacept Approval Letter 1/30/03. FDA/ Office of Therapeutics Research and Review, 2003. Available from www.fda. gov/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ ApprovalApplications/ TherapeuticBiologicApplications/ ucm128088.htm). [Accessed 2003]
9. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64
10. Shapira MY, Resnick IB, Dray L, et al. A new induction protocol for the control of steroid refractory/dependent acute graft versus host disease with alefacept and tacrolimus. Cytotherapy 2009;11:61-7
11. AMEVIVE (alefacept) package insert Biogen, INC. Available from: http:// www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ ApprovalApplications/ TherapeuticBiologicApplications/ ucm086009.pdf). [Accessed 2003]
12. Goedkoop AY, de Rie MA, Picavet DI, et al. Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res 2004;295:465-73
13. Prasertsuntarasai T, Bello EF. Mycobacterium avium complex olecranon bursitis in a patient treated with alefacept. Mayo Clin Proc 2005;80:1532-3
14. Thaci D, Patzold S, Kaufmann R, Boehncke WH. Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. Br J Dermatol 2005;152:1048-50
15. da Silva AJ, Brickelmaier M, Majeau GR, et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/ CD16-dependent apoptosis of CD2(+) cells. J Immunol 2002;168:4462-71
16. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-55
17. Cooper JC, Morgan G, Harding S, et al. Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol 2003;33:666-75
18. Vaishnaw AK, TenHoor CN. Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn 2002;29:415-26
19. Gottlieb AB, Casale TB, Frankel E, et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol 2003;49:816-25
20. Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol 2003;4:131-9
21. Lowe NJ, Gonzalez J, Bagel J, et al. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol 2003;42:224-30
22. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821-33
23. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-27 •• One of the pivotal trials that led to the approval of alefacept.
24. Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003;206:307-15
25. Ortonne JP, Lebwohl M, Em Griffiths C. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol 2003;13:117-23 • This reference highlights the drop in lymphocytes, which is a mechanism by which alefacept works.
26. Menter A, Cather JC, Baker D, et al. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006;54:61-3 •• This article demonstrates repeated efficacy of alefacept in responders.
27. Gribetz CH, Blum R, Brady C, et al. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol 2005;53:73-5 • This article demonstrates that 16 weeks of treatment with alefacept works better than 12 weeks.
28. Cafardi JA, Cantrell W, Wang W, et al. The safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasis. Skinmed 2008;7:67-72
29. Krell J, Nelson C, Spencer L, Miller S. An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis. J Am Acad Dermatol 2008;58:609-16
30. Korver JE, Langewouters AM, Van De Kerkhof PC, Pasch MC. Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venereol 2006;20:1252-5
31. Brimhall AK, King LN, Licciardone JC, et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008;159:274-85
32. Goffe B, Papp K, Gratton D, et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 2005;27:1912-21
33. Moul DK, Routhouska SB, Robinson MR, Korman NJ. Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2008;58:984-9
34. Simon D, Wittwer J, Kostylina G, et al. Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 2008;122:423-4
35. O'Neill ID. Off-label use of biologicals in the management of inflammatory oral mucosal disease. J Oral Pathol Med 2008;37:575-81
36. Chang AL, Badger J, Rehmus W, Kimball AB. Alefacept for erosive lichen planus: a case series. J Drugs Dermatol 2008;7:379-83
37. Kraan MC, van Kuijk AW, Dinant HJ, et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002;46:2776-84
38. Mease PJ, Reich K. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2009;60:402-11
39. Heffernan MP, Hurley MY, Martin KS, et al. Alefacept for alopecia areata. Arch Dermatol 2005;141:1513-6
40. Foss CE, Clark AR, Inabinet R, et al. An open-label pilot study of alefacept for the treatment of pyoderma gangrenosum. J Eur Acad Dermatol Venereol 2008;22:943-9
41. Guenther LC. Alefacept is safe and efficacious in the treatment of palmar plantar pustulosis. J Cutan Med Surg 2007;11:202-5
42. Carr D, Tusa MG, Carroll CL, et al. Open label trial of alefacept in palmoplantar pustular psoriasis. J Dermatolog Treat 2008;19:97-100
43. Myers W, Christiansen L, Gottlieb AB. Treatment of palmoplantar psoriasis with intramuscular alefacept. J Am Acad Dermatol 2005;53:S127-9
44. Shapira MY, Resnick IB, Bitan M, et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant 2005;36:1097-101
45. Shapira MY, Resnick IB, Dray L, et al. A new induction protocol for the control of steroid refractory/dependent acute graft versus host disease with alefacept and tacrolimus. Cytotherapy 2009;11:61-7
46. Shapira MY, Abdul-Hai A, Resnick IB, et al. Alefacept treatment for refractory chronic extensive GVHD. Bone Marrow Transplant 2009;43:339-43
47. Stotler CJ, Eghtesad B, Hsi E, Silver B. Rapid resolution of GVHD after orthotopic liver transplantation in a patient treated with alefacept. Blood 2009;113:5365-6
48. Hurd DS, Johnston C, Bevins A. A case report of Hailey-Hailey disease treated with alefacept (Amevive). Br J Dermatol 2008;158:399-401
49. Garcia-Zuazaga J, Korman NJ. Cutaneous sarcoidosis successfully treated with alefacept. J Cutan Med Surg 2006;10:300-3
50. Al-Mutairi N, Al-Doukhi A. Familial coexisting and colocalized psoriasis and vitiligo responding to alefacept. J Cutan Med Surg 2009;13:172-5
51. Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine - Levels of Evidence. 2009. Available from: http://www.cebm.net/ index.aspx?o=1025